US FDA Panel Rejects Trelegy Ellipta COPD Mortality Claim; Worries Include Potential Overuse

 
• By Sue Sutter
FDA Advisory Committee Feature image
Panel votes 14-1 against mortality benefit labeling for Trelegy Ellipta.

More from US FDA Performance Tracker

More from Regulatory Trackers